Type 1 diabetes remains a daily management challenge. The disease results from permanent loss of insulin-producing beta cells and, despite modern tools, people living with Type 1 diabetes face continuous risk of both high and low glucose. The author, an endocrinologist, notes that the median age at diagnosis is 24 years and that adults now represent the majority of cases — a demographic shift with implications for long-term care needs. Advances such as fast-acting insulins, continuous glucose monitoring (CGM) and automated insulin delivery (AID) have improved control for many, but they have not eliminated serious risks.
Clinically important harms persist. Insulin’s narrow therapeutic index means both underdosing and overdosing carry acute danger: hypoglycemia can lead to seizure, loss of consciousness, or death; hyperglycemia raises the risk of diabetic ketoacidosis and long-term microvascular and macrovascular complications. The article cites U.S. prevalence of roughly 2.1 million people living with type 1 diabetes, all of whom require lifelong insulin and ongoing monitoring. Even when glycemic targets are met, investigators reported continued elevations in rates of retinopathy, cardiovascular disease and mortality compared with the general population.
Fear of low glucose shapes behavior. The clinician-author describes patients who intentionally run higher glucose levels to avoid hypoglycemia in safety-sensitive situations, which can lead to chronic hyperglycemia. Symptoms of lows vary widely: some people perceive shakiness and confusion early, while others have impaired awareness of hypoglycemia (IAH) and may not sense declines until they become severe. The clinical definition now used for severe hypoglycemic events focuses on altered mental or physical function requiring assistance from another person, regardless of measured glucose level — a definition that aims to standardize recognition and reporting.
Underreporting is common and consequential. The study team observed that many severe lows occur at home and therefore do not appear in medical records; in one cited survey about 40% of respondents did not discuss a severe hypoglycemic event with their providers. The same retrospective analysis of adults using advanced technologies found that approximately 43% were not meeting HbA1c <7% and that roughly 20% reported at least one severe low in the prior year, with about 12% reporting two or more. Recurrent severe lows associate with reduced quality of life, increased hospitalizations, higher cardiovascular risk and other adverse outcomes. The ICD-10 update in October 2024 added codes for hypoglycemia levels 1–3 and clarified that level 3 (E16.A3) corresponds to events requiring third-party assistance.
Exogenous insulin and technology do not fully re-create physiologic insulin secretion. Investigators are therefore exploring beta cell replacement strategies that aim to restore endogenous insulin production and reduce reliance on exogenous insulin. The article frames these approaches as potentially beneficial for people who struggle most with glycemic management and recurrent severe hypoglycemia. It also stresses that current replacement strategies have limitations that constrain their broader use.
Deceased donor islet transplantation has been studied for more than 20 years. The therapy uses islets isolated from donor pancreases and typically infuses them into the liver via the portal vein. Published outcomes have demonstrated that recipients can achieve near-normoglycemia and elimination of severe hypoglycemia; such results are often associated with two to three infusions in the literature. The procedure is approved by the FDA for certain individuals, yet access remains limited. The study team reported barriers including donor pancreas scarcity and variability in islet quality. In addition, recipients require lifelong immunosuppression to prevent rejection of transplanted cells.
Whole pancreas transplantation can restore endogenous insulin production and, in some cases, eliminate the need for exogenous insulin. This option is most commonly offered to people with type 1 diabetes who are undergoing kidney transplantation or who have severe, refractory glycemic instability. As with other organ transplants, lifelong immunosuppression is required to maintain graft viability and prevent immune-mediated loss of function.
Research continues into manufactured islet cell therapies and next-generation technologies. The article notes investigational efforts aimed at creating cell-based products that could address donor scarcity and variability in cell quality. Additionally, work is under way on disease-modifying therapies to delay or prevent onset, as well as on improved closed-loop systems and personalized digital health tools to reduce burden. The source did not report specific trial protocols, dosing, efficacy data, timelines or regulatory milestones for these investigational approaches; those details remain to be published by the study teams.
Limitations and unresolved questions remain concrete and immediate. Donor availability and variable islet quality constrain current transplantation approaches. Lifelong immunosuppression poses risks that limit candidacy. Access is narrow even when therapies have regulatory approval. The article ends by pointing to these gaps — open clinical questions include how manufactured cell products will perform long term, whether they can avoid immunosuppression, and when broader access can be achieved — items that the source identifies but for which it does not provide specific answers or timelines.